Search

Your search keyword '"Susan Asirvatham"' showing total 4 results
Start Over Author "Susan Asirvatham" Publisher wiley
4 results on '"Susan Asirvatham"'

1. Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms

Author

Andrea Duminuco, Joshua Au Yeung, Raj Vaghela, Sukhraj Virdee, Claire Woodley, Susan Asirvatham, Natalia Curto‐Garcia, Priya Sriskandarajah, Jennifer O'Sullivan, Hugues deLavallade, Deepti Radia, Shahram Kordasti, Giuseppe Palumbo, Claire Harrison, and Patrick Harrington

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2024
Full Text
View/download PDF

2. Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021

Author

Jamie Saunders, Natalia Curto-Garcia, Priya Sriskandarajah, Jennifer O’Sullivan, Claire Woodley, Susan Asirvatham, Marion Campbell-Drew, Jonathan Mathias, Tim Ellis, Nona Baker, Deepti H. Radia, Sahra Ali, Shahram Kordasti, Patrick Harrington, Hugues de Lavallade, Donal P. McLornan, and Claire N. Harrison

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2021
Full Text
View/download PDF

3. Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center

Author

Alesia Khan, Claire Woodley, Deepti Radia, George N. Mikhaeel, Jessica Brady, Natalia Curto Garcia, Patrick Harrington, Jennifer O’Sullivan, Shahram Kordasti, Yvonne Francis, Susan Asirvatham, Sahra Ali, Priya Sriskandarajah, Jamie Saunders, Hugues de Lavallade, Donal P. McLornan, and Claire N. Harrison

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2021
Full Text
View/download PDF

4. <scp>Chronic myeloid leukaemia</scp> patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype

Author

Patrick Harrington, Richard Dillon, Deepti Radia, Donal McLornan, Claire Woodley, Susan Asirvatham, Kavita Raj, Natalia Curto‐Garcia, Jamie Saunders, Shahram Kordasti, Claire Harrison, and Hugues de Lavallade

Subjects
Phenotype, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Humans, Hematology, Protein Kinase Inhibitors, T-Lymphocytes, Regulatory
Abstract

The search for novel targets in chronic myeloid leukaemia (CML) is ongoing, to improve treatment efficacy in refractory disease and increase eligibility for tyrosine kinase inhibitor (TKI) discontinuation. Increased frequency of Tregs and effector Tregs was evident at diagnosis, together with increased expression of T-cell exhaustion markers, including in regulatory T cells at diagnosis and in patients with refractory disease. Plasma analysis revealed significantly increased levels of cytokines including tumour necrosis factor (TNF)-a and interleukin (IL)-6 at diagnosis, in keeping with a pro-inflammatory state prior to treatment. We hence demonstrate T-cell exhaustion and a pro-inflammatory state at diagnosis in CML, likely secondary to leukaemia-associated antigenic overload associated with increased disease burden.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results